Merck and Moderna’s experimental personalized mRNA cancer vaccine has cleared a major clinical hurdle: when paired with the immunotherapy Keytruda, it reduced the risk of melanoma recurrence or death by 42 percent compared with Keytruda alone. The Phase 3 INTerpath-001 trial enrolled 1,137 people with high-risk, completely resected stage IIB through IV cutaneous melanoma, giving the companies their strongest evidence yet that individualized cancer vaccines can help prevent tumors from returning. The headline result came after a median follow-up of 24.6 months.
The treatment, known as intismeran autogene, V940, or mRNA-4157, is designed around the mutations found in an individual patient’s tumor. Researchers analyze tumor and normal DNA, select as many as 34 tumor-specific neoantigens, and create a custom mRNA sequence intended to teach T cells what that patient’s cancer looks like. Keytruda, or pembrolizumab, works differently: it blocks the PD-1 immune checkpoint, helping release T cells from one of the mechanisms tumors use to evade attack. The combination therefore pairs a personalized target list with a broader immune-system boost. Merck’s trial announcement describes the study as randomized, double-blind, and placebo-controlled.
Patients received up to nine doses of intismeran every three weeks alongside Keytruda, while the control group received Keytruda and placebo. At two years, 82.2 percent of patients in the combination arm remained recurrence-free, compared with 70 percent of those receiving Keytruda alone. The vaccine combination also lowered the risk of distant metastasis or death by 38 percent, an important distinction because melanoma that spreads beyond its original site becomes substantially harder to control. Reuters’ coverage likewise reported the two-year cancer-free rates and characterized the findings as a potential step toward more individualized treatment.
The results also show why the word “vaccine” can be misleading if it conjures up a one-size-fits-all shot. This is not intended to prevent melanoma before it appears, and it is not a universal product that every patient receives in the same form. Each dose is built from the biology of a particular tumor after surgery. The approach reflects a broader shift in oncology toward using sequencing and computational analysis to identify neoantigens—mutated fragments that may be visible to the immune system but absent from healthy tissue.
There are still important limits to what the trial proves. Overall-survival data are not mature, and the study remains ongoing. During the first six months, when the vaccine regimen was being administered, recurrence outcomes were comparable between the groups; the stronger separation appeared in later analysis. Treatment-related side effects were also common, occurring in 95.8 percent of patients receiving the combination versus 90 percent in the Keytruda-only group. Fever, injection-site pain, and fatigue were among the most frequent complaints, while grade 3–5 treatment-related events occurred in 14.2 percent and 13.4 percent of patients, respectively. ClinicalTrials.gov lists INTerpath-001 under NCT05933577.
Intismeran remains investigational rather than an approved melanoma treatment. Merck and Moderna say they are engaging with regulators following the Phase 3 results, which were selected for presentation at the 2026 ESMO Congress and accepted for publication in the New England Journal of Medicine. If the findings withstand full peer review and longer follow-up, the therapy could help establish personalized mRNA treatment as a practical addition to cancer care—not as a replacement for surgery or immunotherapy, but as a custom-built partner intended to keep high-risk disease from coming back.
